Lantheus Q1 revenue $377.3M (+1.2% YoY); GAAP EPS $1.80, adjusted EPS $1.46

Lantheus Holdings, Inc.

2026-Q1 EPS reported $1.80 revenue$377,333,000

Worldwide revenue $377.3M (+1.2%); GAAP diluted EPS $1.80 (+76.5%), adjusted diluted EPS $1.46 (-4.6%).
PYLARIFY sales $240.9M (-6.5% YoY); DEFINITY $84.6M (+6.8%); Neuraceq $35.4M.
FDA approved PYLARIFY TruVu (new formulation); phased launch begins Q4 2026.
FDA tentative approval for PNT2003 (Lutetium Lu 177 Dotatate radioequivalent for GEP-NETs); launch pending.
Reaffirmed FY2026 guidance: revenue $1.4B-$1.45B, adjusted EPS $5.00-$5.25.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Lantheus Holdings, Inc. updated its the three months ended March 31, 2026 guidance (reaffirmed).

Period: the three months ended March 31, 2026
Guidance: reaffirmed
Result: reported results

Exact text from the filing

On May 7, 2026, Lantheus Holdings, Inc. (the “Company”) announced via press release its financial results as of and for the three months ended March 31, 2026. A copy of that press release is being furnished as Exhibit 99.1 and is hereby incorporated by reference.

View on SEC.gov

Browse all earnings releases →

Lantheus Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-210369

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.